News
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Read More on BOLT: ...
CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...
Nearly 50% of experts expect this to have the most promising innovation pipeline. Immuno-oncology (IO) drugs are poised to revolutionise cancer treatment in the next five years, according to a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback